WO2002043666A3 - Composition et methode - Google Patents

Composition et methode Download PDF

Info

Publication number
WO2002043666A3
WO2002043666A3 PCT/US2001/048665 US0148665W WO0243666A3 WO 2002043666 A3 WO2002043666 A3 WO 2002043666A3 US 0148665 W US0148665 W US 0148665W WO 0243666 A3 WO0243666 A3 WO 0243666A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
antioxidant
carnitine
preventing
cognitive function
Prior art date
Application number
PCT/US2001/048665
Other languages
English (en)
Other versions
WO2002043666A2 (fr
Inventor
Steven Curtis Zicker
Karen J Wedekind
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/922,633 external-priority patent/US20020052402A1/en
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Priority to CA002427470A priority Critical patent/CA2427470A1/fr
Priority to JP2002545645A priority patent/JP2004514686A/ja
Priority to AU2002232616A priority patent/AU2002232616A1/en
Priority to EP01992146A priority patent/EP1339404A2/fr
Publication of WO2002043666A2 publication Critical patent/WO2002043666A2/fr
Publication of WO2002043666A3 publication Critical patent/WO2002043666A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Birds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition renfermant un antioxydant ou un mélange d'antioxydants en quantités suffisantes pour prévenir, inhiber, ou inverser la détérioration de la fonction cognitive.
PCT/US2001/048665 2000-10-31 2001-10-30 Composition et methode WO2002043666A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002427470A CA2427470A1 (fr) 2000-10-31 2001-10-30 Composition et methode
JP2002545645A JP2004514686A (ja) 2000-10-31 2001-10-30 組成物と方法
AU2002232616A AU2002232616A1 (en) 2000-10-31 2001-10-30 Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin C or vitamin E for preventing or inhibiting loss of cognitive function
EP01992146A EP1339404A2 (fr) 2000-10-31 2001-10-30 Composition et methode

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US24451100P 2000-10-31 2000-10-31
US60/244,511 2000-10-31
US25344600P 2000-11-28 2000-11-28
US25344700P 2000-11-28 2000-11-28
US60/253,447 2000-11-28
US60/253,446 2000-11-28
US09/922,633 2001-08-06
US09/922,633 US20020052402A1 (en) 2000-10-31 2001-08-06 Composition and method

Publications (2)

Publication Number Publication Date
WO2002043666A2 WO2002043666A2 (fr) 2002-06-06
WO2002043666A3 true WO2002043666A3 (fr) 2003-01-30

Family

ID=27500158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/048665 WO2002043666A2 (fr) 2000-10-31 2001-10-30 Composition et methode

Country Status (6)

Country Link
EP (1) EP1339404A2 (fr)
JP (1) JP2004514686A (fr)
CN (1) CN1477958A (fr)
AU (1) AU2002232616A1 (fr)
CA (1) CA2427470A1 (fr)
WO (1) WO2002043666A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005185188A (ja) * 2003-12-25 2005-07-14 Nichirei Corp アセロラ処理物およびｌ−カルニチン含有組成物
CN1917779B (zh) * 2004-01-28 2010-06-16 雀巢技术公司 用于改善皮肤状况和防止皮肤病的营养组合物
AU2005309502B2 (en) * 2004-11-24 2011-11-17 Hill's Pet Nutrition, Inc. Methods for increasing the immune response in an animal
BRPI0518580A2 (pt) * 2004-11-24 2008-11-25 Hills Pet Nutrition Inc mÉtodo para melhorar a depuraÇço hepÁtica de substÂncias xenobiàticas em um animal, kit adequado para alimentar Ácido lipàico a um animal, meio para comunicar informaÇço, composiÇço, e, uso da composiÇço que compreende Ácido lipàico
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
WO2007022344A2 (fr) * 2005-08-17 2007-02-22 Hill's Pet Nutrition, Inc. Procedes et compositions permettant de prevenir et de traiter les maladies renales
CN1895671B (zh) * 2005-12-08 2012-11-28 淮北辉克药业有限公司 治疗病毒型肝病的复方制剂
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
EP2123263A1 (fr) * 2007-02-14 2009-11-25 Tohoku University Composition et procédé pour supprimer la péroxydation des lipides dans les érythrocytes
US20120288608A1 (en) * 2009-07-14 2012-11-15 Hill's Pet Nutrition, Inc. Pet food compositions including a sustained-release lipoic acid and methods of manufacture and use thereof
EP2508179A1 (fr) 2011-04-05 2012-10-10 Lonza Ltd. Utilisation de carnitine L, sels et dérivés associés pour réduire ou empêcher la fatigue et améliorer la fonction cognitive
JP2014532032A (ja) 2011-04-05 2014-12-04 ロンザ・リミテッド 疲労を減少させるためまたは予防するためおよび認知機能を改善するためのｌ−カルニチン、その塩および誘導体の使用
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06199690A (ja) * 1992-03-06 1994-07-19 Yunie:Kk 脳代謝促進・脳機能改善剤
DE4343592A1 (de) * 1993-12-21 1995-06-22 Asta Medica Ag Verwendung von R-(+)alpha-Liponsäure, R-(-)-Dihydroliponsäure und deren Metabolite in Form der freien Säure oder als Salze oder Ester oder Amide zur Herstellung von Arzneimitteln zur Behandlung von Glukosestoffwechselstörungen des zentralen Nervensystem
US5853747A (en) * 1994-06-27 1998-12-29 Institut De Recherche Biologique Therapeutic and dietetic uses of a brain phospholipid-based complex
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
DE19920316A1 (de) * 1999-05-03 1999-12-09 Heinz Kiefer Arzneimittel als Antioxidans mit einer Vitamin-Spurenelement-Kombination zur Förderung der Funktionstüchtigkeit der Zellen
WO2000011968A1 (fr) * 1998-09-01 2000-03-09 Sigma-Tau Healthscience S.P.A. Composition antioxydante renfermant de l'acetyl-l-carnitine et de l'acide alpha-lipoique
WO2000054754A2 (fr) * 1999-03-16 2000-09-21 Merck Patent Gmbh Composition comprenant de l'isoquercetine et de l'acide ascorbique a liberation prolongee
WO2000057876A1 (fr) * 1999-03-26 2000-10-05 Lipogenics, Inc. Preparations antioxydantes et procedes d'utilisation de telles preparations
WO2000076492A1 (fr) * 1999-06-15 2000-12-21 Nutri-Logics, Inc. Compositions de nutriments destines a reduire le risque de maladie, traitement associe, et methode de selection des constituants
WO2001032168A1 (fr) * 1999-11-03 2001-05-10 Juvenon, Inc. Traitement de la perte de memoire benigne
WO2001058271A1 (fr) * 2000-01-25 2001-08-16 Juvenon, Inc. Supplements nutritionnels pour animaux de compagnie ages
WO2001070206A2 (fr) * 2000-03-06 2001-09-27 Javor Andras Combinaison de medicaments

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06199690A (ja) * 1992-03-06 1994-07-19 Yunie:Kk 脳代謝促進・脳機能改善剤
DE4343592A1 (de) * 1993-12-21 1995-06-22 Asta Medica Ag Verwendung von R-(+)alpha-Liponsäure, R-(-)-Dihydroliponsäure und deren Metabolite in Form der freien Säure oder als Salze oder Ester oder Amide zur Herstellung von Arzneimitteln zur Behandlung von Glukosestoffwechselstörungen des zentralen Nervensystem
US5853747A (en) * 1994-06-27 1998-12-29 Institut De Recherche Biologique Therapeutic and dietetic uses of a brain phospholipid-based complex
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
WO2000011968A1 (fr) * 1998-09-01 2000-03-09 Sigma-Tau Healthscience S.P.A. Composition antioxydante renfermant de l'acetyl-l-carnitine et de l'acide alpha-lipoique
WO2000054754A2 (fr) * 1999-03-16 2000-09-21 Merck Patent Gmbh Composition comprenant de l'isoquercetine et de l'acide ascorbique a liberation prolongee
WO2000057876A1 (fr) * 1999-03-26 2000-10-05 Lipogenics, Inc. Preparations antioxydantes et procedes d'utilisation de telles preparations
DE19920316A1 (de) * 1999-05-03 1999-12-09 Heinz Kiefer Arzneimittel als Antioxidans mit einer Vitamin-Spurenelement-Kombination zur Förderung der Funktionstüchtigkeit der Zellen
WO2000076492A1 (fr) * 1999-06-15 2000-12-21 Nutri-Logics, Inc. Compositions de nutriments destines a reduire le risque de maladie, traitement associe, et methode de selection des constituants
WO2001032168A1 (fr) * 1999-11-03 2001-05-10 Juvenon, Inc. Traitement de la perte de memoire benigne
WO2001058271A1 (fr) * 2000-01-25 2001-08-16 Juvenon, Inc. Supplements nutritionnels pour animaux de compagnie ages
WO2001070206A2 (fr) * 2000-03-06 2001-09-27 Javor Andras Combinaison de medicaments

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199433, Derwent World Patents Index; Class B05, AN 1994-269367, XP002210667 *
POULIN J E ET AL: "Vitamin E prevents oxidative modification of brain and lymphocyte band 3 proteins during aging.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 28 MAY 1996, vol. 93, no. 11, 28 May 1996 (1996-05-28), pages 5600 - 5603, XP002210596, ISSN: 0027-8424 *
See also references of EP1339404A2 *

Also Published As

Publication number Publication date
CA2427470A1 (fr) 2002-06-06
WO2002043666A2 (fr) 2002-06-06
EP1339404A2 (fr) 2003-09-03
AU2002232616A1 (en) 2002-06-11
CN1477958A (zh) 2004-02-25
JP2004514686A (ja) 2004-05-20

Similar Documents

Publication Publication Date Title
WO2002043666A3 (fr) Composition et methode
UA100841C2 (en) Normal;heading 1;heading 2;heading 3;STABLE VITAMIN C COMPOSITIONS
HUP0303581A2 (hu) Fenolos antioxidánsok szinergetikus kombinációi
WO2004072168A3 (fr) Compositions de resine
AU2001236497A1 (en) Anhydrous antiperspirant compositions containing water-reactive monomers as antiperspirant active
BR9005011A (pt) Composicao para uso oral
AU2002358163A1 (en) Cosmetic compositions comprising a cyclodipeptide compound
DE60000616D1 (de) Mineralwasser enthaltende Zusammensetzungen
TW200716184A (en) Inhibitor for parakeratosis, pore reducing agent or skin roughening preventing or ameliorating agent and composition for skin care preparation
CA2278133A1 (fr) Compositions de fluoroether et procedes d'inhibition de leur degradation en presence d'un acide de lewis
BRPI0412132A (pt) método para diminuir a deterioração da capacidade mental em um felino, e, composição de dieta felina
WO2003086329A3 (fr) Compositions et methodes de soin de la peau
WO2001093816A3 (fr) Compositions stabilisees renfermant des principes actifs qui sont labiles en presence d'oxygene
AU2002212661A1 (en) Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
IL159554A0 (en) Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same
WO2007058568A3 (fr) Sels et melanges d'acide 9-oxoacridine-10-acetique et de 1-alkylamino-1-desoxypolyols, compositions pharmaceutiques les contenant, et methodes de traitement associees
WO2002083674A3 (fr) Compositions contenant des imidazotriazinones pour application nasale
DK1408966T3 (da) Synergistiske farmaceutiske kombinationer til forebyggelse eller behandling af diabetes
EP1435230A3 (fr) Compositions antisolaire
TW200724603A (en) Polyalkoxylate-comprising solid formulations, processes for their preparation and their use
CA2359491A1 (fr) Melange a composition phytosanitaires avec des cires, sa preparation et son utilisation
UA43402C2 (uk) Фармацевтична композиція, що містить тіагабінгідрохлорид, та спосіб її одержання
WO2000059448A3 (fr) Association d'inhibiteur(s) de no synthase et d'antioxydant(s) metabolique(s)
WO2007071860A3 (fr) Compositions comprenant au moins un composé rétinoide et au moins un composé anti-irritant et leurs utilisations
WO2007034445A3 (fr) Nouveaux derives de la piperazine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 018181880

Country of ref document: CN

Ref document number: 2427470

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002545645

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002232616

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003/03749

Country of ref document: ZA

Ref document number: 200303749

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001992146

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001992146

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001992146

Country of ref document: EP